Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Setting up for standardization
November 2018
SHARING OPTIONS:

FREEHOLD, N.J.—Weill Cornell Medicine has chosen GenExosome Technologies’ exosome isolation system to be part of the first standardization processing of cGMP-grade exosomes for clinical studies, as announced by Avalon GloboCare Corp., of which GenExosome is a subsidiary. Dr. Yen-Michael Hsu, director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering at Weill Cornell, will lead a co-development program to standardize cGMP-grade exosome isolation from human endothelial cells and to identify/isolate tissue-specific exosomes for liquid biopsy and clinical use. A material transfer agreement will be established to permit Weill Cornell’s use of GenExosome’s system.
 
“Identification and isolation of tissue-specific exosomes is considered by many as the “Holy Grail” in this area. This co-development and standardization initiative with Weill Cornell has further enhanced the global recognition, intellectual property, as well as our leading role in this industry sector,” said Dr. Yu Zhou, founder and co-CEO of GenExosome.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.